Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme

Vaccine

Volumn 30, Issue 26, 2012, Pages 3944-3950

  Ingels, Helene ^a   Rasmussen, Jeppe ^b   Andersen, Peter Henrik ^b   Harboe, Zitta B ^a   Glismann, Steffen ^b   Konradsen, Helle ^a   Hoffmann, Steen ^a   Valentiner Branth, Palle ^b   Lambertsen, Lotte ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Department of Epidemiology Research   (Denmark)

Author keywords

Indirect effect; Invasive pneumococcal disease; Mortality; PCV10; PCV13; PCV7; Pneumococcal conjugate vaccine; Serotype replacement

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DENMARK; FATALITY; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MORTALITY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84861189149     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.060     Document Type: Article

References (27)

1. World Health Organization. Acute Respiratory infections; Streptococcus pneumoniae update september 2009, [accessed 28.11.11]. http://www.who.int/vaccine_research/diseases/ari/en/index3.html%23disease%20burden.
2. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003, 348(May (18)):1737-1746.
3. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000, 19(March (3)):187-195.
4. Goldblatt D., Southern J., Ashton L., Andrews N., Woodgate S., Burbidge P., et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatric Infectious Disease Journal 2010, 29(May (5)):401-405.
5. Vestrheim D.F., Høiby E.A., Bergsaker M.R., Rønning K., Aaberge I.S., Caugant D.A. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010, 28(March (10)):2214-2221.
6. Givon-Lavi N., Greenberg D., Ben Shimol S., Dagan R. Rapid reduction in invasive pneumococcal disease (IPD) after introduction of PCV7 to the national immunization plan (NIP) in Israel 2011, Pediatric Infectious Disease Unit, Soroka University Medical Center and Ben-Gurion University of the Negev, Beer-Sheva, Israel, abstract ESPID, Den Hague June.
7. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010, 201:32-41.
8. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R., et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(April (9568)):1179-1186.
9. Miller E.J., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Diseases 2011, May.
10. van Gils E.J., Veenhoven R.H., Hak E., Rodenburg G.D., Keijzers W.C., Bogaert D., et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010, 304(September (10)):1099-1106.
11. van Gils E.J., Hak E., Veenhoven R.H., Rodenburg G.D., Bogaert D., Bruin J.P., et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 2011, 6(6):e20229.
12. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Deursen A., van Mens S., et al, Impact of seven-valent pneumococcal conjugate vaccine on the incidence and serotypedistribution of invasive pneumococcal disease in the Netherlands, abstract ESPID Den Hague, June 2011.
13. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Review of Vaccines 2011, 10(February (2)):187-199.
14. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Andersen P.H., Howitz M., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28(March (14)):2642-2647.
15. http://www.danmap.org/pdfFiles/Danmap_2010.pdf.
16. Harboe Z.B., Benfield T.L., Valentiner-Branth P., Hjuler T., Lambertsen L., Kaltoft M., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clinical Infectious Diseases 2010, 50(February (3)):329-337.
17. Danmarks Statistik, [accessed 28.11.11]. http://www.statistikbanken.dk/statbank5a/default.asp%3Fw=1280.
18. Widgren K., Simonsen J., Valentiner-Branth P., Mølbak K. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Vaccine 2011, 29(December (52)):9663-9667.
19. EPINEWS week 44, 1999.
20. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Hjuler T., Kaltoft M., et al. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine 2008, 26(July (29-30)):3765-3771.
21. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. Journal of Clinical Microbiology 1995, 33(10):2759-2762.
22. Sorensen U.B. Typing of pneumococci by using 12 pooled antisera. Journal of Clinical Microbiology 1993, 31(8):2097-2100.
23. PCV 7 coverage & Invasive Pneumococcal Disease (IPD) 2008-2010, EPI-NEWS week 7/8, 2011. Available at, SSI, 2011. http://www.ssi.dk/English/News/EPI-NEWS/2010/No%207-8%20-%202010.aspx.
24. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Medicine 2009, 6(May 5):e1000081.
25. Weinberger D.M., Harboe Z.B., Sanders E.A., Ndiritu M., Klugman K.P., Rückinger S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clinical Infectious Diseases 2010, 51(September (156)):692-699.
26. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infectious Diseases 2005, 5(2):83-93.
27. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. Journal of Infectious Diseases 2007, 196:1346-1354.